相似文献
1
[Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma].[口腔鳞状细胞癌中程序性死亡受体-1及其配体的研究进展]
Hua Xi Kou Qiang Yi Xue Za Zhi. 2020 Aug 1;38(4):449-453. doi: 10.7518/hxkq.2020.04.017.
2
Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.程序性死亡受体-1 及其配体程序性死亡配体-1 在有和无口腔黏膜下纤维性变的口腔鳞状细胞癌中的差异表达。
Arch Oral Biol. 2020 Nov;119:104916. doi: 10.1016/j.archoralbio.2020.104916. Epub 2020 Sep 17.
3
Difference between Keratinized- and Non-Keratinized-Originating Epithelium in the Process of Immune Escape of Oral Squamous Cell Carcinoma.角化型和非角化型来源的口腔鳞状细胞癌在免疫逃避过程中的差异。
Int J Mol Sci. 2024 Mar 29;25(7):3821. doi: 10.3390/ijms25073821.
4
Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.程序性细胞死亡配体 1 在口腔鳞状细胞癌和口腔白斑病中的表达与疾病进展和 CD8+肿瘤浸润淋巴细胞有关。
Pathol Res Pract. 2019 Jun;215(6):152418. doi: 10.1016/j.prp.2019.04.010. Epub 2019 Apr 18.
5
Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.免疫调节分子 PD-L1 和 PD-1 在口腔癌及癌前病变中的表达：一项日本患者的队列研究。
J Craniomaxillofac Surg. 2019 Jan;47(1):33-40. doi: 10.1016/j.jcms.2017.04.013. Epub 2017 May 10.
6
Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma.X 连锁尿路上皮癌蛋白 9 通过泛素特异性肽酶 9 对程序性细胞死亡配体 1 的去泛素化和稳定作用。
Cancer Med. 2018 Aug;7(8):4004-4011. doi: 10.1002/cam4.1675. Epub 2018 Jul 10.
7
Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.腺苷 2b 受体和程序性死亡配体 1 的共抑制促进口腔鳞状细胞癌中自然杀伤细胞的募集和细胞毒性。
PeerJ. 2023 Aug 30;11:e15922. doi: 10.7717/peerj.15922. eCollection 2023.
8
Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.PD-L1和PD-1表达增加与口腔鳞状细胞癌的淋巴结转移及不良预后显著相关。
Int J Oral Maxillofac Surg. 2018 Jul;47(7):836-845. doi: 10.1016/j.ijom.2018.01.004. Epub 2018 Feb 1.
9
Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma.光化性唇炎和口腔鳞状细胞癌患者中程序性死亡受体 1（PD-1）和 PD-1 配体（PD-L1）表达增强。
Cancer Immunol Immunother. 2011 Jul;60(7):965-74. doi: 10.1007/s00262-011-1007-5. Epub 2011 Mar 27.
10
PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.肿瘤细胞 PD-L1 表达是口腔鳞状细胞癌独立的不良预后因素。
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):546-554. doi: 10.1158/1055-9965.EPI-18-0779. Epub 2018 Nov 28.
引用本文的文献
1
Verification of the expression trend and interaction prediction of innate immune cells and immune-checkpoint molecules in the process of oral mucosal carcinogenesis.验证固有免疫细胞和免疫检查点分子在口腔黏膜癌变过程中的表达趋势和相互作用预测。
Hua Xi Kou Qiang Yi Xue Za Zhi. 2024 Apr 1;42(2):192-206. doi: 10.7518/hxkq.2024.2023280.
2
Fructose-1,6-Bisphosphatase 2 Inhibits Oral Squamous Cell Carcinoma Tumorigenesis and Glucose Metabolism via Downregulation of c-Myc.果糖-1,6-二磷酸酶 2 通过下调 c-Myc 抑制口腔鳞状细胞癌肿瘤发生和葡萄糖代谢。
Oxid Med Cell Longev. 2022 May 6;2022:6766787. doi: 10.1155/2022/6766787. eCollection 2022.
本文引用的文献
1
Novel Delivery Systems for Checkpoint Inhibitors.用于检查点抑制剂的新型递送系统
Medicines (Basel). 2019 Jul 11;6(3):74. doi: 10.3390/medicines6030074.
2
Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence.PD-1/PD-L1 轴在口腔舌鳞癌中的免疫组织化学研究：新辅助化疗对局部复发的影响。
Pathol Oncol Res. 2020 Apr;26(2):735-742. doi: 10.1007/s12253-019-00606-3. Epub 2019 Feb 14.
3
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.帕博利珠单抗对比甲氨蝶呤、多西他赛或西妥昔单抗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-040）：一项随机、开放标签、III 期研究。
Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30.
4
PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.肿瘤细胞 PD-L1 表达是口腔鳞状细胞癌独立的不良预后因素。
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):546-554. doi: 10.1158/1055-9965.EPI-18-0779. Epub 2018 Nov 28.
5
High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.肿瘤细胞中高 PD-L1 表达与口腔鳞状细胞癌患者预后不良无关：文献荟萃分析。
Cell Prolif. 2019 Mar;52(2):e12537. doi: 10.1111/cpr.12537. Epub 2018 Nov 15.
6
Incidence and mortality trends in oral and oropharyngeal cancers in China, 2005-2013.2005 - 2013年中国口腔和口咽癌的发病率及死亡率趋势
Cancer Epidemiol. 2018 Dec;57:120-126. doi: 10.1016/j.canep.2018.10.014. Epub 2018 Nov 2.
7
[Clinicopathological and prognostic significance of PD-L1 expression in oral squamous cell carcinoma: a meta analysis].[程序性死亡配体1（PD-L1）表达在口腔鳞状细胞癌中的临床病理及预后意义：一项荟萃分析]
Shanghai Kou Qiang Yi Xue. 2018 Feb;27(1):100-105.
8
Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management.转移性黑色素瘤免疫检查点抑制治疗的免疫毒性：病例系列与临床管理
J Skin Cancer. 2018 Jan 21;2018:9602540. doi: 10.1155/2018/9602540. eCollection 2018.
9
Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.PD-L1和PD-1表达增加与口腔鳞状细胞癌的淋巴结转移及不良预后显著相关。
Int J Oral Maxillofac Surg. 2018 Jul;47(7):836-845. doi: 10.1016/j.ijom.2018.01.004. Epub 2018 Feb 1.
10
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.纳武利尤单抗联合伊匹单抗治疗错配修复缺陷/微卫星高度不稳定转移性结直肠癌的持久临床获益。
J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
Zotero 插件